Literature DB >> 17188426

Clinical significance of serum angiocidin levels in hepatocellular carcinoma.

Yamini Sabherwal1, Vicki L Rothman, Ronnie T P Poon, George P Tuszynski.   

Abstract

Angiocidin, a tumor-secreted protein, was measured in serum of 27 healthy volunteers and 33 hepatocellular carcinoma (HCC) patients. Healthy controls either hepatitis B surface antigen (HBsAg) positive or negative showed undetectable levels. Patients had levels of angiocidin ranging from 15.09 to 195.73 pg/ml. Patients with stages III-IV had higher levels of angiocidin (97+/-13 pg/ml, n=17) compared to those with stages I-II (63+/-37 pg/ml, n=16), p<0.043. Patients with microsatellite tumor nodules had higher average levels (98+/-55 pg/ml, n=17) compared to those without microsatellite nodules (51+/-27 pg/ml, n=20), p<0.032. Our studies suggest that angiocidin predicts advanced stage and intra-hepatic metastasis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17188426      PMCID: PMC1955767          DOI: 10.1016/j.canlet.2006.10.023

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  15 in total

1.  Satellite lesions in patients with small hepatocellular carcinoma with reference to clinicopathologic features.

Authors:  Takuji Okusaka; Shuichi Okada; Hideki Ueno; Masafumi Ikeda; Kazuaki Shimada; Junji Yamamoto; Tomoo Kosuge; Susumu Yamasaki; Noriyoshi Fukushima; Michiie Sakamoto
Journal:  Cancer       Date:  2002-11-01       Impact factor: 6.860

Review 2.  Treatment of hepatocellular carcinoma: is there an optimal strategy?

Authors:  María Varela; Margarita Sala; Josep M Llovet; Jordi Bruix
Journal:  Cancer Treat Rev       Date:  2003-04       Impact factor: 12.111

3.  Integrin alpha2beta1 mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated protein.

Authors:  Yamini Sabherwal; Vicki L Rothman; Svetoslav Dimitrov; Darryl Z L'Heureux; Cezary Marcinkiewicz; Mahesh Sharma; George P Tuszynski
Journal:  Exp Cell Res       Date:  2006-04-30       Impact factor: 3.905

4.  Enhanced expression of mRNAs of antisecretory factor-1, gp96, DAD1 and CDC34 in human hepatocellular carcinomas.

Authors:  K Tanaka; N Kondoh; M Shuda; O Matsubara; N Imazeki; A Ryo; T Wakatsuki; A Hada; N Goseki; T Igari; K Hatsuse; T Aihara; S Horiuchi; N Yamamoto; M Yamamoto
Journal:  Biochim Biophys Acta       Date:  2001-04-30

5.  The localization of thrombospondin-1 (TSP-1), cysteine-serine-valine-threonine-cysteine-glycine (CSVTCG) TSP receptor, and matrix metalloproteinase-9 (MMP-9) in colorectal cancer.

Authors:  T Wakiyama; T Shinohara; T Shirakusa; A S John; G P Tuszynski
Journal:  Histol Histopathol       Date:  2001-04       Impact factor: 2.303

6.  Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1.

Authors:  Jing Zhou; Vicki L Rothman; Irene Sargiannidou; Svetoslav Dimitrov; Cuie Qiu; Elana Smith; Joel Sheffield; Mahesh Sharma; George P Tuszynski
Journal:  J Cell Biochem       Date:  2004-05-01       Impact factor: 4.429

7.  Localization of thrombospondin and its cysteine-serine-valine-threonine-cysteine-glycine-specific receptor in human breast carcinoma.

Authors:  G P Tuszynski; R F Nicosia
Journal:  Lab Invest       Date:  1994-02       Impact factor: 5.662

8.  Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma.

Authors:  Ronnie T Poon; Ka Kit Chung; Siu Tim Cheung; Cecilia P Lau; See Wai Tong; Ka Ling Leung; Wan Ching Yu; George P Tuszynski; Sheung Tat Fan
Journal:  Clin Cancer Res       Date:  2004-06-15       Impact factor: 12.531

9.  Computer-assisted image analysis of tumor sections for a new thrombospondin receptor.

Authors:  J P Arnoletti; D Albo; N Jhala; M S Granick; M P Solomon; B Atkinson; V L Rothman; G P Tuszynski
Journal:  Am J Surg       Date:  1994-11       Impact factor: 2.565

10.  Identification and characterization of a tumor cell receptor for CSVTCG, a thrombospondin adhesive domain.

Authors:  G P Tuszynski; V L Rothman; M Papale; B K Hamilton; J Eyal
Journal:  J Cell Biol       Date:  1993-01       Impact factor: 10.539

View more
  4 in total

1.  Reduction of angiocidin contributes to decreased HepG2 cell proliferation.

Authors:  X G Guan; X Q Guan; K Feng; R Jian; D Tian; D Tian; H B Tong; X Sun
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

2.  The interaction of angiocidin with tissue transglutaminase.

Authors:  Darryl Z L'Heureux; Vicki L Rothman; George P Tuszynski
Journal:  Exp Mol Pathol       Date:  2009-11-18       Impact factor: 3.362

3.  The novel angiogenic inhibitor, angiocidin, induces differentiation of monocytes to macrophages.

Authors:  Anita Gaurnier-Hausser; Vicki L Rothman; Svetoslav Dimitrov; George P Tuszynski
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

4.  Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: exploring the functional significance in tumor cell invasion.

Authors:  Anitha S John; Xioulong Hu; Vicki L Rothman; George P Tuszynski
Journal:  Exp Mol Pathol       Date:  2009-09-09       Impact factor: 3.362

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.